LENZ THERAPEUTICS, INC. Operating Lease, Expense
LENZ THERAPEUTICS, INC. (LENZ) reported Operating Lease, Expense of $100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-06-30 was $100.00K, a 0.00% change year-over-year.
- LENZ THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-03-31 was $100.00K, a 0.00% change year-over-year.
- LENZ THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-12-31 was $100.00K, a 50.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-09-30 was $100.00K, a 0.00% change year-over-year.
- LENZ THERAPEUTICS, INC. operating lease, expense for fiscal 2025 was $500.00K, a 25.00% increase from fiscal 2024.
- LENZ THERAPEUTICS, INC. operating lease, expense for fiscal 2024 was $400.00K, a 300.00% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $100.00K, a 98.51% decline from fiscal 2022.
- LENZ THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $6.70M, a 252.63% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.00K 10-Q · filed 2026-08-11 | $200.00K 10-Q · filed 2026-08-11 | $300.00K derived: sum of 3 quarters · filed 2026-08-11 | $400.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-11 | $200.00K derived: sum of 2 quarters · filed 2026-05-11 | $300.00K derived: sum of 3 quarters · filed 2026-05-11 | $400.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $200.00K derived: sum of 2 quarters · filed 2026-03-24 | $300.00K derived: sum of 3 quarters · filed 2026-08-11 | $500.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-05 | $200.00K derived: sum of 2 quarters · filed 2026-08-11 | $400.00K 10-Q · filed 2025-11-05 | $500.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-11 | $300.00K 10-Q · filed 2026-08-11 | $400.00K derived: sum of 3 quarters · filed 2026-08-11 | $500.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-11 | $300.00K derived: sum of 2 quarters · filed 2026-05-11 | $400.00K derived: sum of 3 quarters · filed 2026-05-11 | $500.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $300.00K derived: sum of 2 quarters · filed 2026-03-24 | $400.00K derived: sum of 3 quarters · filed 2026-03-24 | $400.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-05 | $200.00K derived: sum of 2 quarters · filed 2025-11-05 | $200.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $100.00K 10-Q · filed 2025-07-30 | $100.00K 10-Q · filed 2025-07-30 | ||
| 2023-12-31 | -$6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$3.90M derived: sum of 2 quarters · filed 2025-03-19 | -$1.60M derived: sum of 3 quarters · filed 2025-03-19 | $100.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $2.40M 10-Q · filed 2023-11-13 | $4.70M derived: sum of 2 quarters · filed 2023-11-13 | $6.40M 10-Q · filed 2023-11-13 | $8.10M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $2.30M 10-Q · filed 2023-08-14 | $4.00M 10-Q · filed 2023-08-14 | $5.70M derived: sum of 3 quarters · filed 2023-08-14 | $7.40M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $1.70M 10-Q · filed 2023-05-11 | $3.40M derived: sum of 2 quarters · filed 2023-05-11 | $5.10M derived: sum of 3 quarters · filed 2023-11-13 | $6.70M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $3.40M derived: sum of 2 quarters · filed 2023-11-13 | $5.00M derived: sum of 3 quarters · filed 2023-11-13 | $6.70M 10-K · filed 2023-03-20 |
| 2022-09-30 | $1.70M 10-Q · filed 2023-11-13 | $3.30M derived: sum of 2 quarters · filed 2023-11-13 | $5.00M 10-Q · filed 2023-11-13 | $6.10M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.60M 10-Q · filed 2023-08-14 | $3.30M 10-Q · filed 2023-08-14 | $4.40M derived: sum of 3 quarters · filed 2023-08-14 | $5.00M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.70M 10-Q · filed 2023-05-11 | $2.80M derived: sum of 2 quarters · filed 2023-05-11 | $3.40M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $1.70M derived: sum of 2 quarters · filed 2023-03-20 | $1.90M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $600.00K 10-Q · filed 2021-11-10 | $800.00K 10-Q · filed 2021-11-10 | ||
| 2020-12-31 | $300.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |